New Science Ventures

Pakal Technologies is a semiconductor manufacturing company focused on transforming the IGBT market through its innovative IGTO-based semiconductors. These semiconductors utilize IGTO, a silicon device designed as a direct replacement for traditional IGBTs, offering substantial performance improvements. By providing efficient, scalable, and compatible solutions, Pakal Technologies aims to address longstanding power conversion challenges and deliver enhanced capabilities to its clients.

Glydways, formerly known as Wayfarer, is a transportation technology and clean energy company located in South San Francisco, California. The company focuses on designing, manufacturing, installing, and operating affordable autonomous transportation systems that cater to various capacity needs, including low, medium, and extremely high-capacity demands. Glydways aims to transform mobility and public transportation by providing a system that operates profitably at existing mass transit fares. Its solutions are designed for efficiency, featuring a small physical and environmental footprint, with zero greenhouse gas emissions. By offering a personal, private car experience, Glydways enhances passenger capacity while minimizing costs and environmental impact.

Glydways, formerly known as Wayfarer, is a transportation technology and clean energy company located in South San Francisco, California. The company focuses on designing, manufacturing, installing, and operating affordable autonomous transportation systems that cater to various capacity needs, including low, medium, and extremely high-capacity demands. Glydways aims to transform mobility and public transportation by providing a system that operates profitably at existing mass transit fares. Its solutions are designed for efficiency, featuring a small physical and environmental footprint, with zero greenhouse gas emissions. By offering a personal, private car experience, Glydways enhances passenger capacity while minimizing costs and environmental impact.

VUV Analytics, Inc. specializes in the manufacture and marketing of vacuum ultraviolet (VUV) detectors, which enhance chemical analysis accuracy through advanced spectroscopy techniques. Established in 2009 as a spin-off from a semiconductor equipment company, VUV Analytics leverages the expertise of its founders, who possess extensive knowledge in hardware, software, analysis, and intellectual property related to VUV technologies. The company offers products such as the VGA-100, a VUV absorption spectroscopy instrument, and gas chromatography detectors, which are utilized for both identification and quantification of various compounds. Its technology finds applications across multiple industries, including petroleum and natural gas, environmental science, petrochemicals, agrochemicals, and food and beverage safety. VUV Analytics is headquartered in Cedar Park, Texas, and has developed a substantial intellectual property portfolio, including numerous issued and pending patents.

Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.

Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.

Analog Inference is a company focused on advancing neural computing through innovative technology. Founded by experienced professionals from the computing industry and supported by Khosla Ventures, the company is developing its first generation of products. It specializes in deep sub-threshold analog in-memory computation, which allows for the execution of complex neural networks at full resolution while maintaining low latency and eliminating the need for active cooling. This technology enables the performance of data-center-grade artificial intelligence workloads with significantly reduced power consumption, facilitating the deployment of server-class networks in more cost-effective devices.

Phase Four LLC is a manufacturer of satellite propulsion systems based in Pasadena, California, founded in 2015. The company specializes in electric propulsion for small satellites, offering innovative products such as the CubeSats ambipolar thruster and the Maxwell plasma propulsion solution. Its core technology, the Radio Frequency Thruster (RFT), distinguishes itself by eliminating the need for a hollow cathode and high voltage electronics, resulting in significant cost savings, reduced size of power electronics, and compatibility with various propellants. Phase Four's propulsion systems are designed to be small and lightweight, featuring a patented magnetic nozzle to optimize thrust, allowing clients to effectively maneuver satellites into various orbits while minimizing operational costs. The company's products are utilized across commercial, civil, and scientific space missions, reflecting its commitment to advancing the capabilities of space exploration.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Zeotap GmbH operates a customer intelligence platform that assists brands in understanding their customers and predicting their behavior. Founded in 2014 and headquartered in Berlin, Germany, with additional offices in New York, Bengaluru, Madrid, and Milan, Zeotap offers three main data solutions. The Zeotap Customer Data Platform (CDP) enables brands to integrate, unify, segment, and orchestrate customer data securely. Zeotap Data facilitates effective targeting through the activation of a wide range of Champion Segments across numerous programmatic and social platforms. Additionally, Zeotap ID+ serves as a universal marketing ID initiative, ensuring addressability in a cookieless future. The platform adheres to data privacy and security standards, allowing companies to manage and monetize diverse datasets while leveraging first-party data to enhance customer acquisition and loyalty.

ABL Space Systems specializes in designing and manufacturing rockets for the launch of small satellites. Incorporated in 2017 and based in El Segundo, California, the company focuses on developing low-cost and reliable launch vehicles, with its primary product being the RS1 rocket. This vehicle is capable of carrying payloads of up to 1,350 kilograms to Low Earth Orbit (LEO) and supports various configurations, including multi-manifest and dedicated deployments. In addition to the RS1, ABL also creates the GS0 ground system, which facilitates rapid deployment and integration of launch operations at multiple sites. The company operates from a 30,000 square foot facility dedicated to research, development, and production, and is privately owned, supported by a group of private equity investors.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

DUST Identity, Inc. specializes in developing an authentication system that employs nano-diamonds to create an unclonable identity layer on various objects for supply chains. This technology, known as DUST, links physical items to their digital records, allowing for secure verification and authentication. The company also offers an optical scanner and a cloud-based infrastructure that facilitates access to object identity and provenance information. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, DUST Identity aims to ensure that trusted data and verifiable products can be traced throughout their lifecycle, thus enhancing safety and reliability in product sourcing, testing, and certification.

PlanetIQ LLC, founded in 2012 and based in Bethesda, Maryland, specializes in launching satellites to deliver critical weather forecasting, climate monitoring, and space weather prediction services. The company addresses the increasing demand for accurate weather data amid rising natural disaster costs and population growth. By utilizing commercial satellite constellations, PlanetIQ provides timely data essential for improving decision-making processes across various sectors. This initiative aims to enhance the precision of weather and climate models, which are increasingly reliant on high-quality data for forecasts ranging from hourly to decadal. As traditional government-funded satellite programs struggle with aging technology and budget constraints, PlanetIQ fills vital gaps in data necessary for monitoring daily weather patterns, hurricanes, floods, droughts, and climate change, ultimately helping clients mitigate weather-related risks and enhance safety.

Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.

DUST Identity, Inc. specializes in developing an authentication system that employs nano-diamonds to create an unclonable identity layer on various objects for supply chains. This technology, known as DUST, links physical items to their digital records, allowing for secure verification and authentication. The company also offers an optical scanner and a cloud-based infrastructure that facilitates access to object identity and provenance information. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, DUST Identity aims to ensure that trusted data and verifiable products can be traced throughout their lifecycle, thus enhancing safety and reliability in product sourcing, testing, and certification.

Svelte Medical Systems, Inc. specializes in the design, development, and commercialization of balloon-expandable stents aimed at patients undergoing percutaneous coronary intervention (PCI) for atherosclerosis treatment. The company offers the SLENDER Integrated Delivery System, a drug-eluting coronary stent-on-a-wire system that simplifies catheter use for transradial interventions, and the DIRECT Rapid Exchange System, which employs proprietary balloon designs to improve direct stenting and post-dilatation processes. Founded in 2007 by Robert, David, and Tim Fischell, Svelte is committed to addressing critical clinical challenges in the coronary stent market, focusing on enhancing stent deliverability, reducing costs, and improving device safety. The company has developed one of the lowest profile and most deliverable stents available, featuring advanced technology aimed at achieving better clinical outcomes for patients. Based in New Providence, New Jersey, Svelte operates within the $5 billion coronary stent market.

Isorg SA, founded in 2010 and based in Grenoble, France, specializes in the development and manufacturing of organic and printed electronic devices, particularly in the fields of photonics and image sensors. The company is noted for its innovative high-performance opto-electronic sensors, which can be integrated into various products, transforming surfaces made of plastic or glass into smart interfaces. Isorg offers a comprehensive range of services, from proof-of-concept to mass production, catering to diverse applications across consumer electronics, home appliances, smart buildings, industrial sectors, healthcare, and safety. Additionally, the company provides support for product development and integration. Its technology includes large-area image sensors and photodetectors, contributing to sectors such as medical imaging, non-destructive testing, and data security.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.

ChromaCure is engaged in the development of innovative cancer therapies, focusing on discovering first-in-class small molecule therapeutics to address unmet needs in oncology. The company is initiating a drug development program aimed at identifying new candidates that selectively and potently inhibit cancer targets. This initiative seeks to provide novel treatment options for multiple forms of cancer, either as standalone therapies or in combination with existing immunotherapy or chemotherapy approaches. Through its efforts, ChromaCure aims to enhance the therapeutic landscape for cancer patients, offering potential new solutions for various cancer types.

Escalier Biosciences B.V., established in 2016 and headquartered in Nijmegen, Netherlands, is a biopharmaceutical company focused on developing novel small molecule therapeutics for autoimmune disorders, particularly psoriasis. The company is advancing its lead drug candidates, which are designed to target ROR?t, through late-stage preclinical studies. Escalier's therapeutics enhance penetration in dermal tissues, optimizing target engagement at sites of inflammation while reducing the potential for systemic side effects and immune suppression. In addition to its operations in the Netherlands, Escalier also maintains an office in Encinitas, California.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Zeotap GmbH operates a customer intelligence platform that assists brands in understanding their customers and predicting their behavior. Founded in 2014 and headquartered in Berlin, Germany, with additional offices in New York, Bengaluru, Madrid, and Milan, Zeotap offers three main data solutions. The Zeotap Customer Data Platform (CDP) enables brands to integrate, unify, segment, and orchestrate customer data securely. Zeotap Data facilitates effective targeting through the activation of a wide range of Champion Segments across numerous programmatic and social platforms. Additionally, Zeotap ID+ serves as a universal marketing ID initiative, ensuring addressability in a cookieless future. The platform adheres to data privacy and security standards, allowing companies to manage and monetize diverse datasets while leveraging first-party data to enhance customer acquisition and loyalty.

Caringo, Inc. is a software provider specializing in object storage solutions designed for managing unstructured data. Their flagship product, CAStor, facilitates private cloud storage and allows customers to create robust storage clusters without reliance on proprietary hardware. The company also offers various solutions, including Content Router for data distribution, FileFly for managing infrequently accessed data, and Elastic Content Protection for flexible data protection tailored to specific storage needs. Additionally, CloudScaler enables organizations to provide cloud storage as a service, while Indexer provides insights into data stored on the platform. With a customer base that spans from small and medium-sized businesses to Fortune 500 companies, Caringo focuses on delivering scalable, affordable, and efficient data management solutions. Founded in 2005 and based in Austin, Texas, the company emphasizes simplicity and a customer-centric approach in its offerings.

BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.

VUV Analytics, Inc. specializes in the manufacture and marketing of vacuum ultraviolet (VUV) detectors, which enhance chemical analysis accuracy through advanced spectroscopy techniques. Established in 2009 as a spin-off from a semiconductor equipment company, VUV Analytics leverages the expertise of its founders, who possess extensive knowledge in hardware, software, analysis, and intellectual property related to VUV technologies. The company offers products such as the VGA-100, a VUV absorption spectroscopy instrument, and gas chromatography detectors, which are utilized for both identification and quantification of various compounds. Its technology finds applications across multiple industries, including petroleum and natural gas, environmental science, petrochemicals, agrochemicals, and food and beverage safety. VUV Analytics is headquartered in Cedar Park, Texas, and has developed a substantial intellectual property portfolio, including numerous issued and pending patents.

Kateeva, formerly known as TJet Technologies, specializes in developing inkjet printing equipment for the production of organic light-emitting diode (OLED) displays. The company's innovative manufacturing solutions enable the mass production of flexible and large-size OLEDs, offering significant advantages in terms of longer lifespans, higher yields, and reduced production costs. This technology represents a breakthrough in the display industry, making it economically viable to produce OLEDs at scale. Kateeva's equipment can print billions of pixels rapidly, paving the way for advanced flat panel displays, including flexible and foldable products. This advancement not only enhances consumer electronics, making high-quality displays more accessible, but also fosters a new wave of innovation in the technology sector.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Svelte Medical Systems, Inc. specializes in the design, development, and commercialization of balloon-expandable stents aimed at patients undergoing percutaneous coronary intervention (PCI) for atherosclerosis treatment. The company offers the SLENDER Integrated Delivery System, a drug-eluting coronary stent-on-a-wire system that simplifies catheter use for transradial interventions, and the DIRECT Rapid Exchange System, which employs proprietary balloon designs to improve direct stenting and post-dilatation processes. Founded in 2007 by Robert, David, and Tim Fischell, Svelte is committed to addressing critical clinical challenges in the coronary stent market, focusing on enhancing stent deliverability, reducing costs, and improving device safety. The company has developed one of the lowest profile and most deliverable stents available, featuring advanced technology aimed at achieving better clinical outcomes for patients. Based in New Providence, New Jersey, Svelte operates within the $5 billion coronary stent market.

Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics aimed at treating inflammatory and fibrotic diseases. Headquartered in Cambridge, United Kingdom, with an additional office in San Diego, California, the company has been working on a lead program involving a non-bile acid FXR agonist. This therapeutic candidate targets nonalcoholic steatohepatitis (NASH), a progressive fatty-liver disease for which there are currently no approved treatment options. As of August 2016, Akarna operates as a subsidiary of Allergan plc. The lead candidate is in the preclinical phase, undergoing toxicology and safety pharmacology studies, with plans for first-in-human trials in the near future.

Ovizio specializes in digital holographic interferometric microscopy, creating advanced 4D microscopic imaging devices and associated software. The company targets scientists and biomanufacturers by offering automated cell culture monitoring and analysis systems that enhance the scaling of cell culture processes. Its technology is primarily aimed at the life sciences sector, specifically in bioprocessing and research and development. By utilizing digital holographic microscopy, Ovizio provides innovative solutions that support the growth and efficiency of scientific operations.

Fuzzy Logix, LLC is an analytics software and professional services company that specializes in in-database analytics solutions. Its flagship product, DB Lytix, is a computation engine designed for quantitative analysts and application developers, allowing them to perform analytics directly within the database. This capability eliminates the need for data extraction and reduces reliance on additional servers, leading to significant time and cost savings. The company also offers a range of financial analytics solutions, including tools for portfolio management and time series analysis, as well as a graphics processing unit analytic appliance pre-loaded with a comprehensive library of algorithms. Additionally, Fuzzy Logix provides various advisory services, such as analytics and technology consulting, cloud analytics, and custom model development. Its products and services cater to a diverse clientele across sectors like finance, insurance, marketing, retail, and healthcare, and are available through direct sales and resellers both in the United States and internationally. Founded in 1995, Fuzzy Logix is headquartered in Charlotte, North Carolina.

EXTEN Technologies, Inc. specializes in designing, developing, and manufacturing high-performance non-volatile memory flash storage solutions tailored for web-scale, enterprise, and cloud data centers. The company focuses on accelerating application workloads while minimizing system power consumption, offering products such as flash storage arrays and solid-state drives. EXTEN's technology is particularly suited for demanding applications requiring low-latency and high performance, including e-commerce, real-time analytics, and financial transactions. Additionally, EXTEN provides support services, training, and professional design assistance to enhance customer experience. Founded in 2011 and based in Austin, Texas, EXTEN operates as a subsidiary of OVH SAS, leveraging a global network of resellers and partners to reach its clients.

VORAGO Technologies Inc. is a fabless semiconductor company specializing in the design, manufacture, and testing of radiation-hardened and extreme temperature-hardened integrated circuit (IC) components. The company provides high-density SRAMs and microcontrollers tailored for applications across the automotive, industrial, military, aerospace, and networking sectors. VORAGO is known for its proprietary HARDSIL technology, which enhances the endurance of ICs against radiation and temperature extremes without requiring redesign. This innovative approach enables the production of robust CMOS circuits suitable for harsh environments, offering a reliable alternative to traditional high-reliability solutions. Additionally, VORAGO offers custom application-specific integrated circuit (ASIC) design services using its hardened Metal Programmable System On Chip (MPSoC) platform. Founded in 2004 and headquartered in Austin, Texas, VORAGO Technologies was previously known as Silicon Space Technology Corporation before rebranding in 2015.

Ralexar Therapeutics, Inc. is a biopharmaceutical company focused on developing and manufacturing topical and systemic therapies that utilize Liver X Receptor (LXR) modulators. The company targets a range of cutaneous inflammatory disorders, with a particular emphasis on atopic dermatitis. Founded in 2013 and headquartered in Wayne, Pennsylvania, Ralexar is known for its clinical development of ALX-101, a topical therapy designed to improve treatment outcomes for patients with dermatological conditions. Originally established as Alexar Therapeutics, the company rebranded in March 2016 and operates as a subsidiary of NeXeption, LLC.

PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.

Vaultive specializes in cloud data encryption services that address the critical challenge of securing data in the cloud. By employing advanced encryption-in-use technology, Vaultive enables businesses to maintain control and ownership of their data, even as they transition to cloud applications. Customers retain their encryption keys, ensuring they can utilize cloud services while adhering to necessary governance and security requirements. This approach allows encrypted data to be processed—searched, indexed, and sorted—within cloud applications without needing to be decrypted first. As a result, organizations can benefit from the cost-effectiveness and efficiency of cloud computing while upholding the data security, control, and compliance standards typically associated with on-premise solutions.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Kateeva, formerly known as TJet Technologies, specializes in developing inkjet printing equipment for the production of organic light-emitting diode (OLED) displays. The company's innovative manufacturing solutions enable the mass production of flexible and large-size OLEDs, offering significant advantages in terms of longer lifespans, higher yields, and reduced production costs. This technology represents a breakthrough in the display industry, making it economically viable to produce OLEDs at scale. Kateeva's equipment can print billions of pixels rapidly, paving the way for advanced flat panel displays, including flexible and foldable products. This advancement not only enhances consumer electronics, making high-quality displays more accessible, but also fosters a new wave of innovation in the technology sector.

Svelte Medical Systems, Inc. specializes in the design, development, and commercialization of balloon-expandable stents aimed at patients undergoing percutaneous coronary intervention (PCI) for atherosclerosis treatment. The company offers the SLENDER Integrated Delivery System, a drug-eluting coronary stent-on-a-wire system that simplifies catheter use for transradial interventions, and the DIRECT Rapid Exchange System, which employs proprietary balloon designs to improve direct stenting and post-dilatation processes. Founded in 2007 by Robert, David, and Tim Fischell, Svelte is committed to addressing critical clinical challenges in the coronary stent market, focusing on enhancing stent deliverability, reducing costs, and improving device safety. The company has developed one of the lowest profile and most deliverable stents available, featuring advanced technology aimed at achieving better clinical outcomes for patients. Based in New Providence, New Jersey, Svelte operates within the $5 billion coronary stent market.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

Ario Pharma Ltd is focused on developing therapeutic drugs for respiratory conditions, particularly through the evaluation of XEN-D0501, a potential leading TRPV1 inhibitor. The company is conducting two Phase 2 clinical trials to assess the anti-tussive properties of this drug. In addition to its respiratory portfolio, Ario also works on small-molecule TRPV1 antagonists aimed at treating neuropathic and inflammatory pain. The firm is backed by a skilled development team and supported by leading experts in respiratory diseases, ensuring a robust approach to drug development.

BrightVolt, Inc. specializes in the design, development, and mass production of ultra-thin film batteries tailored for various Internet-connected devices, including medical patches, sensor labels, and power cards. The company also creates custom solid-state thin film batteries and power solutions specifically for clients' IoT applications, alongside its Flexion solid-state lithium polymer batteries and thin microelectronics. BrightVolt's patented technology enhances battery chemistry by improving stability and abuse tolerance, allowing for the manufacture of high-energy-density, safe, and reliable solid-state batteries. Based in Redmond, Washington, the company markets its products both domestically and internationally. Founded in 1998, BrightVolt was previously known as Solicore, Inc.

Dezima Pharma B.V., founded in 2012 and based in Naarden, the Netherlands, focuses on developing protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company is known for its innovative approach in creating a cholesteryl ester transfer protein inhibitor, which serves as a pharmacological therapy to reduce low-density lipoprotein cholesterol levels. By lowering these cholesterol levels, Dezima Pharma aims to provide clinicians with effective treatment options for patients suffering from dyslipidemia and related cardiovascular conditions.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. Established in 2010, the company is advancing its lead biologic compounds, including RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby reducing kidney damage and interferon activation. Additionally, Resolve Therapeutics is progressing RSLV-133, a bi-specific Fc-nuclease fusion protein that integrates dual nuclease activities into a single therapeutic molecule. The company's research is rooted in significant discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a commitment to enhancing the quality of life for patients affected by these challenging conditions.

Achronix Semiconductor Corp. is a privately held fabless company based in Santa Clara, California, specializing in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, is built on Intel's advanced 22nm process technology and incorporates fully integrated hard IP protocol functions, making it suitable for communications applications. Achronix also offers Speedcore eFPGA IP for integration into customers' system-on-chip designs, as well as a comprehensive design tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. The company's products cater to various markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security sectors. Achronix sells its products through distributors across North America, Europe, Israel, China, and Russia. Founded in 2004, Achronix has research and development facilities in both Santa Clara and Bangalore, India.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.

Vaultive specializes in cloud data encryption services that address the critical challenge of securing data in the cloud. By employing advanced encryption-in-use technology, Vaultive enables businesses to maintain control and ownership of their data, even as they transition to cloud applications. Customers retain their encryption keys, ensuring they can utilize cloud services while adhering to necessary governance and security requirements. This approach allows encrypted data to be processed—searched, indexed, and sorted—within cloud applications without needing to be decrypted first. As a result, organizations can benefit from the cost-effectiveness and efficiency of cloud computing while upholding the data security, control, and compliance standards typically associated with on-premise solutions.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

Oxyrane UK Limited is a biopharmaceutical company focused on developing innovative enzyme replacement therapies for lysosomal storage diseases, which encompass over 40 rare inherited disorders. Established in 2006 and headquartered in Manchester, United Kingdom, the company utilizes a proprietary glycoengineering platform based on the yeast Yarrowia lipolytica to produce human lysosomal enzymes that enhance enzyme uptake and localization in patients. Oxyrane's approach aims to expedite treatment initiation and improve the chances of successful outcomes for individuals affected by these conditions. Additionally, the company operates research facilities in Ghent, Belgium, and maintains a presence in Burlington, Massachusetts.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. Established in 2010, the company is advancing its lead biologic compounds, including RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby reducing kidney damage and interferon activation. Additionally, Resolve Therapeutics is progressing RSLV-133, a bi-specific Fc-nuclease fusion protein that integrates dual nuclease activities into a single therapeutic molecule. The company's research is rooted in significant discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a commitment to enhancing the quality of life for patients affected by these challenging conditions.

Lightwire is a telecommunications company focused on providing internet, voice, and data solutions for businesses. It specializes in the development of interconnect solutions that utilize CMOS photonics technology to enhance high-speed connectivity. The company's offerings include Ethernet optoelectronic interconnects and optical transceiver modules designed for networking, communication, server, and storage systems. These products enable networking equipment manufacturers to create plug-and-play 10Gbps interfaces, facilitating efficient connections between computers, servers, and network devices within Ethernet-based networks. Lightwire aims to integrate optical and electrical solutions to power the next generation of high-speed interconnects.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

ProterixBio, Inc. develops disease management platforms aimed at improving outcomes for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company focuses on creating proprietary blood-based biomarker tests that provide real-time biological assessments of a patient's disease state. Its ViBE platform, along with Acoustic Membrane MicroParticle (AMMP) assays, utilizes advanced technology to enhance the sensitivity and specificity of traditional diagnostic methods by analyzing proteins in blood, sputum, and other samples. By offering tools that enable healthcare providers to better manage patients, ProterixBio aims to reduce unnecessary hospitalizations and associated healthcare costs. Founded in 2002 and headquartered in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in 2016.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Achronix Semiconductor Corp. is a privately held fabless company based in Santa Clara, California, specializing in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, is built on Intel's advanced 22nm process technology and incorporates fully integrated hard IP protocol functions, making it suitable for communications applications. Achronix also offers Speedcore eFPGA IP for integration into customers' system-on-chip designs, as well as a comprehensive design tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. The company's products cater to various markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security sectors. Achronix sells its products through distributors across North America, Europe, Israel, China, and Russia. Founded in 2004, Achronix has research and development facilities in both Santa Clara and Bangalore, India.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

TherOx, Inc. is a medical device company based in Irvine, California, focused on enhancing the treatment of heart attack patients through its innovative dissolved oxygen delivery systems. The company's primary offering, SuperSaturated Oxygen Therapy (SSO2), utilizes the TherOx DownStream system, which combines a mobile device with a cartridge to create superoxygenated blood. This blood is then delivered directly to the coronary arteries to improve blood flow and promote healing of damaged heart tissue. Founded in 1994, TherOx has conducted extensive research through benchtop studies, animal studies, and clinical trials to validate its technology. In addition to heart attacks, the company is exploring the use of SSO2 therapy in other medical fields, including stroke, oncology, and wound care. TherOx holds 20 issued patents, with further applications pending, reflecting its commitment to advancing medical treatment standards. As of June 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation.

BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Ikonisys, Inc. is a medical diagnostic company focused on the design, manufacture, and marketing of advanced diagnostic products for cancer detection and genetic disorder screening. Headquartered in New Haven, Connecticut, Ikonisys offers a range of innovative tools, including the Ikoniscope Robotic Microscope, which automates slide handling and image analysis, reducing human error in testing. Their product line features various oncoFISH applications, such as those for bladder cancer and HER2 status in breast tissue, as well as tools for detecting genetic abnormalities in prostate tissue biopsies. The company is committed to transforming diagnostic medicine by enabling early and accurate disease detection through a combination of cutting-edge technology and scientific research, ultimately assisting healthcare professionals in providing optimal patient care. Founded in 1999, Ikonisys continues to advance its capabilities in non-invasive diagnostic solutions.

FlowCardia, Inc. is a medical device company established in 2002, specializing in the design and development of catheter-based technologies aimed at overcoming chronic total occlusions (CTOs) in coronary and peripheral arteries. CTOs present significant challenges in interventional therapy, often resulting in patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia's innovative solutions seek to address this critical gap in treatment options, enhancing the safety and efficacy of procedures for patients with these difficult-to-treat conditions.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Xoft, Inc. specializes in developing electronic brachytherapy (eBx) systems for radiation oncology applications. The company offers a range of products, including the Axxent Controller, which employs a miniaturized high dose rate X-ray source to deliver radiation directly to cancerous tumor beds. Other products include the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, Xoft provides various accessories such as physics accessory kits, personnel protective shields, and patient care kits, along with FlexiShield, designed to minimize radiation exposure to healthy tissues and organs. The company's products are primarily utilized in the treatment of early stage breast cancer, skin cancer, and endometrial cancer. Xoft distributes its offerings through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, the company was previously known as Xoft microTube, Inc. before rebranding in 2004.

Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for unmet medical needs. Founded by experienced pharmaceutical executives, the company is engaged in creating new drugs and treatments for challenging illnesses. Its product portfolio includes Reslizumab, which is aimed at treating eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents that have the potential for oral administration. Additionally, Ception's offerings encompass treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. The company's research pipeline focuses on developing new compounds and expanding indications for existing therapies.

Achronix Semiconductor Corp. is a privately held fabless company based in Santa Clara, California, specializing in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, is built on Intel's advanced 22nm process technology and incorporates fully integrated hard IP protocol functions, making it suitable for communications applications. Achronix also offers Speedcore eFPGA IP for integration into customers' system-on-chip designs, as well as a comprehensive design tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. The company's products cater to various markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security sectors. Achronix sells its products through distributors across North America, Europe, Israel, China, and Russia. Founded in 2004, Achronix has research and development facilities in both Santa Clara and Bangalore, India.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Ikonisys, Inc. is a medical diagnostic company focused on the design, manufacture, and marketing of advanced diagnostic products for cancer detection and genetic disorder screening. Headquartered in New Haven, Connecticut, Ikonisys offers a range of innovative tools, including the Ikoniscope Robotic Microscope, which automates slide handling and image analysis, reducing human error in testing. Their product line features various oncoFISH applications, such as those for bladder cancer and HER2 status in breast tissue, as well as tools for detecting genetic abnormalities in prostate tissue biopsies. The company is committed to transforming diagnostic medicine by enabling early and accurate disease detection through a combination of cutting-edge technology and scientific research, ultimately assisting healthcare professionals in providing optimal patient care. Founded in 1999, Ikonisys continues to advance its capabilities in non-invasive diagnostic solutions.

Light Sciences Oncology, Inc. is focused on developing and manufacturing talaporfin sodium, a water-soluble drug designed for the treatment of solid tumors. The company offers a single-use disposable device that employs LED technology to provide a fixed light dose, enhancing the effectiveness of the drug. Talaporfin sodium is utilized in treating various conditions, including hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia. Founded in 1994, Light Sciences Oncology is headquartered in Bellevue, Washington, and also engages in research and development services for oncology drugs.

TherOx, Inc. is a medical device company based in Irvine, California, focused on enhancing the treatment of heart attack patients through its innovative dissolved oxygen delivery systems. The company's primary offering, SuperSaturated Oxygen Therapy (SSO2), utilizes the TherOx DownStream system, which combines a mobile device with a cartridge to create superoxygenated blood. This blood is then delivered directly to the coronary arteries to improve blood flow and promote healing of damaged heart tissue. Founded in 1994, TherOx has conducted extensive research through benchtop studies, animal studies, and clinical trials to validate its technology. In addition to heart attacks, the company is exploring the use of SSO2 therapy in other medical fields, including stroke, oncology, and wound care. TherOx holds 20 issued patents, with further applications pending, reflecting its commitment to advancing medical treatment standards. As of June 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.